Tscan Therapeutics Stock Total Debt
| TCRX Stock | USD 1.91 0.14 6.83% |
Tscan Therapeutics fundamentals help investors to digest information that contributes to Tscan Therapeutics' financial success or failures. It also enables traders to predict the movement of Tscan Stock. The fundamental analysis module provides a way to measure Tscan Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tscan Therapeutics stock.
Total Debt To Capitalization is likely to rise to 0.36 in 2025. Tscan | Total Debt |
Tscan Therapeutics Company Total Debt Analysis
Tscan Therapeutics' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Tscan Therapeutics Total Debt | 92.43 M |
Most of Tscan Therapeutics' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tscan Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Tscan Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Tscan Therapeutics is extremely important. It helps to project a fair market value of Tscan Stock properly, considering its historical fundamentals such as Total Debt. Since Tscan Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tscan Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tscan Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Tscan Total Debt Historical Pattern
Today, most investors in Tscan Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Tscan Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Tscan Therapeutics total debt as a starting point in their analysis.
Tscan Therapeutics Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Tscan Short Long Term Debt Total
Short Long Term Debt Total |
|
Based on the latest financial disclosure, Tscan Therapeutics has a Total Debt of 92.43 M. This is 96.64% lower than that of the Biotechnology sector and 71.54% lower than that of the Health Care industry. The total debt for all United States stocks is 98.26% higher than that of the company.
Tscan Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tscan Therapeutics' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tscan Therapeutics could also be used in its relative valuation, which is a method of valuing Tscan Therapeutics by comparing valuation metrics of similar companies.Tscan Therapeutics is currently under evaluation in total debt category among its peers.
Tscan Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Tscan Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Tscan Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Tscan Therapeutics' value.| Shares | Abrdn Plc | 2024-12-31 | 883.7 K | State Street Corp | 2024-12-31 | 800.9 K | Dc Funds, Lp | 2024-12-31 | 630 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 412.9 K | Northern Trust Corp | 2024-12-31 | 322.1 K | Dimensional Fund Advisors, Inc. | 2024-12-31 | 280 K | Tocqueville Asset Management L.p. | 2024-12-31 | 260.9 K | Goldman Sachs Group Inc | 2024-12-31 | 160.7 K | Bank Of America Corp | 2024-12-31 | 150.1 K | Ecor1 Capital, Llc | 2024-12-31 | 5 M | Blackrock Inc | 2024-12-31 | 5 M |
Tscan Fundamentals
| Return On Equity | -0.56 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | (31.10) % | ||||
| Current Valuation | (64.93 M) | ||||
| Shares Outstanding | 52.23 M | ||||
| Shares Owned By Insiders | 0.82 % | ||||
| Shares Owned By Institutions | 85.16 % | ||||
| Number Of Shares Shorted | 1.82 M | ||||
| Price To Earning | 23.45 X | ||||
| Price To Book | 0.51 X | ||||
| Price To Sales | 12.37 X | ||||
| Revenue | 21.05 M | ||||
| Gross Profit | (91.04 M) | ||||
| EBITDA | (80.1 M) | ||||
| Net Income | (89.22 M) | ||||
| Cash And Equivalents | 125.6 M | ||||
| Cash Per Share | 5.22 X | ||||
| Total Debt | 92.43 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 7.53 X | ||||
| Book Value Per Share | 4.29 X | ||||
| Cash Flow From Operations | (61.36 M) | ||||
| Short Ratio | 6.00 X | ||||
| Earnings Per Share | (0.95) X | ||||
| Target Price | 12.14 | ||||
| Number Of Employees | 188 | ||||
| Beta | 0.87 | ||||
| Market Capitalization | 115.84 M | ||||
| Total Asset | 272.15 M | ||||
| Retained Earnings | (247.6 M) | ||||
| Working Capital | 164.42 M | ||||
| Net Asset | 272.15 M |
About Tscan Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tscan Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tscan Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tscan Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Tscan Stock Analysis
When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.